Features Screener Stocks Charts
Sign In Sign Up

Glenmark Pharmaceuticals Ltd. Cash Flow Statement

NSE:GLENMARK | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

-0.59x

GLENMARK's operating cash flow was significantly below net income in FY 2025, suggesting earnings include substantial non-cash items.

Free Cash Flow

₹-15.77B

GLENMARK's free cash flow was negative at ₹-15.77B in FY 2025, down 35.5% from FY 2024. The company spent more on capital investments than it generated from operations.

Dividend Coverage

-22.4x

GLENMARK's free cash flow did not fully cover dividends in FY 2025. The company may be funding dividends from reserves or borrowings.

2-year GLENMARK cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 5.69B 13.99B
Cash flow Operating Activities -2.65B -8.28B
Investments in PPE -8.98B -7.50B
Cash flow Investing Activities 45.61B 20.94M
Dividend Paid -1.18B -704.42M
Cash flow Financing Activities -39.06B 7.87B
Cash at beginning of period 14.43B 16.58B
Cash at end of period 16.58B 16.76B
Free Cash Flow -11.64B -15.77B

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025